How do you approach ADT use in a salvage RT patient with biochemical recurrence whose Decipher score is very high but PAM50 subtype is non-luminal B?

Yes, especially if PSA is more than 0.5 ng/mL.

What the new SPPORT data add. The newly reported PAM50 analysis of NRG/RTOG-0534 (SPPORT) is an important step for molecular subtyping in the salvage setting. It includes 709 patients with 7.9 years of median follow-up. In multivariable analysis, Luminal B tumors had a worse prognosis than non-Lumin...

One principle taught to me by a senior medical oncologist shortly after I completed residency was that we should not punish patients for having cancers with unfavorable biology. There is a natural temptation to treat an aggressive cancer with everything available, including our most intensive and to...

In the Decipher Score (DS) analysis in NRG/RTOG-0534 (Pollack et al., ASCO 2025), “There was no significant DS-related benefit to adding STADT to PBRT”. In the current study, when comparing FFP between Arm 1 (PBRT) vs. Arm 2 (PBRT + STADT), the ADT HR was 0.73 (P=0.15) in the non-LumB patients and 0...